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CARDIOVASCULAR EFFECTS 
OF ENKEPHALINS 
Enkephalins and their receptors are found 
in neurons and nerve terminals known to 
be involved in central cardiovascular con-
trol as well as the peripheral sympathetic 
and parasympathetic systems. Enkepha-
lins and opioid receptors were also iden ti-
fied in the heart, kidneys, and blood ves-
sels. The enkephalins interact with several 
specific receptors, of which p, 0, and K have 
been best characterized. Enkephalins ad-
ministered to humans or animals produce 
cardiovascular effects which depend on the 
spedes, route of administration, anes-
thesia, and the selectivity for receptor sub-
type. While little information exists on the 
role of enkephalins in normal cardiovas-
cular control, current data suggest that en-
kephalins might have a role in cardiovas-
cular stress responses such os in shock and 
trauma. 
BACKGROUND 
Introduction 
T he endogenous opioid system includes three major families of peptides (1): enkephalins (derived from pre-proenkephalin A), endorphins (derived from 
pre-proopiomelanoeortin), and dynorphins (derived from 
pre-proenkephalin B). The opioid peptides possess di-
verse autonomie functions through modulation of the 
sympathetie and parasympathetie nervous system and 
baroreflexes. These aetions are mediated by multiple 
forms of opioid reeeptors (2). Sinee multiple forms of 
opioid peptides and multiple reeeptor subtypes exist, the 
opioid effects on the cardiovaseular system are eomplex. 
This article foeuses on the endogenous enkephalin sys-
tem and its potential role in cardiovaseular regulation in 
normal and shock states. 
Distribution of Enkephaffns In the Body 
The distribution of enkephalins and their reeeptors in 
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the central nervous system has been extensively studied. 
Enkephalin-containing neurons are found throughout 
the brain and spinal cord (1). Proenkephalin-eontaining 
perikarya and fibers are found in most forebrain regions, 
including the cerebral cortex. amygdala, hippocampus, 
septum, preoptie area, and most hypothalamic and tha-
lamic nuclei. In the pons, enkephalin neurons are found 
in the parabrachial, dorsal tegmental, vestibular. and 
raphe nudei; in the medulla oblongata, they are found 
in the nucleus retieularis gigantocellularis, nucleus trae-
tus solitarius, and spinal cord dorsal gray (1). In addition 
to these areas, numerous other brain regions contain 
varying densities of enkephalinergie fibers and nerve 
terminals (1). Opioid receptors have also been identified 
in these brain areas (2). 
Outside the central nervous system enkephalins are 
found in plasma (3). to which they are released from the 
pituitary and the adrenal gland (4). In addition, enkeph-
alins are present in eardiovascular organs including the 
heart (5,6), blood vessels (7), adrenal medulla, and auto-
nomie nerves (7). The enkephalins found in the he art 
are located in nerve endings (5). 
Opioid receptors have also been identified in peripheral 
organs such as the heart (8-10), blood vessels (11), and 
kidney (9). In the he art, opiate reeeptor eoneentration in 
the atria is twice as mueh as in the ventricles (8). ehar-
acterization of the opioid-binding sites in the atria sug-
gests the presenee of ö and K but not JL reeeptors in the 
rat atrium (8). 
CURRENT STATUS 
Enkephalins and Central Cardlovascular Control 
Exogenous enkephalins produce different effects on 
blood pressure and he art rate depending on the route of 
administration, speeies, and the presence of anesthesia 
(for review, see 12). Pressor responses and tachyeardia 
follow the lateral cerebral ventricle administration, but 
hypotension and bradycardia are observed after systemic 
injections of methionine-enkephalin and leueine-en-
kephalin in anesthetized rats (13). However, in the eon-
scious rat, methionine or leucine-enkephalins produce 
pressor responses (14). The differences in opioid effects 
after systemic versus central administration are often 
used to indicate a lack of penetration in suffident quan-
tiUes to the cardiovaseular sites in the brain. However, 
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the contrast between these routes of administration can 
be ~he resul,t of opp~sit~ effect of the peptide in different 
bram nuclel, resultmg In summation response with little 
or no effe~t on the gross cardiovascular variables. For 
example, m the hypothalamus, pressor and depressor 
sites f~r m~rphin~ and o-~la2,o-Leu5-enkephalin Were 
found 10 nelghbormg nuclel, which were less than 1 mm 
from each other (15).lnjections ofthe enkephalin analog 
o-Ala2-Met3-enkephalin into the pressor area of the ros-
tral ve~trolateral medulla induced hypotension and bra-
?ycardla responses (16), while injections of this analog 
mto the ventrolateral vasodepressor areas increased 
blood pressure and heart rate (17). Opposite blood pres-
sure responses can be produced by injections of various 
enkephalin analogs into the anterior hypothalamus of 
pentobarbitone-anesthetized rats versus conscious rats: 
hypotension and bradycardia in the anesthetized versus 
in?reases in blood pressure and heart rate in the con~ 
SClOUS animals (18,19). 
Development of new selective agonists and antagonists 
for the multiple opioid receptors has made it possible to 
study the effects of different opioid receptor stimulation 
in discrete brain nuclei. For example, o-Ala2-MePhe4-
G!y5-ol-enkephalin (DAGO) and dermorphin (20) are 
hlghly selective ligands for the JL opioid receptor; 0-
Ala2,o-Leu5-enkephalin is a relatively selective agonist 
to a opioid receptors (a > p.), and dynorphin A species 
and the benzomorphans (bremazocine) aet mainlyon the 
K opioid receptor. Microinjections of low to median doses 
of the p. agonists DAGO, dermorphin, morphiceptin, and 
morphine produce a pressor effect with bradycardic/ 
tachycardic responses in the hypothalamic paraventric-
ular or medial preoptic nuclei (15,18,19,21); high doses 
of p. receptor agonists ultimately lead to cardiovascular 
collapse and death. Pressor and tachycardic responses to 
DAGO have also been described after application into 
nucleus ambigus or nucleus tractus solitarius of anesthe-
tized rats (22,23). In the rat, fl opioid receptor stimulation 
in the nucleus tractus soHtarius also attenuates barore-
flexes (23,24). Blood pressure and heart rate responses 
similar to those produced by DAGO can also be induced 
by the relatively selective ~ agonist o-Ala2,o-Leu5-en-
kephalin. However, the a agonist is about 10-fold less 
potent than tha JL agonist in eliciting cardiovascular 
effects (15,18,19). Thus, the p. opioid receptors rather 
than 0 receptors seem to be the primary receptors in 
mediating the pressor and tachycardic actions of enkeph~ 
alins in the brain. Interestingly, microinjection of various 
K opioid receptor agonists into the paraventricular nuclei, 
medial preoptic nuclei, nucleus ambigus, or nucleus 
tractus solitarius results in decreases in blood pressure 
and heart rate (25,26). Thus, two opioid systems opposing 
each other seem to exist: a fl opioid receptor dependent 
pressor system versus a ,. opioid receptor related depres~ 
sorsystem. 
In addition to hemodynamic changes, enkephalins in the 
brain activate the sympatho-adrenomedullary system 
(19,27,28). Again, this effect seems to be mediated by the 
p. opioid receptors. However, activation of the parasym-
pathetic system has also bean suggested (19) although 
controversy exists in this matter (23). 
P.rlph.ral Cardlovascular EIf.cls of Enk.phallns 
Reaent studies have shown the presence of enkephalins 
and opioid reaeptors in heart, blood vessels, autonomie 
nerves, and adrenal medulla (see above). In isolated 
parfused haart preparations, enkephalins have been 
found to antagonize the effects of adrenergic agonists by 
a calcium-dependent mechanism (29). In vitro, opioid 
peptides acting on K opioid receptors have been shown 
to inhibit norepinephrine release in rabbit and guinea 
pig hearts (10,30). However, no evidence for the endog-
enous opioid peptides in modulation of epinephrine re-
lease was found in these studies. 
In rabbit ear artery preparation, [Leu]-enkephalin was 
found to depress the vasoconstrictor responses to field 
stimulation by a ~ and K opioid receptor media ted mech-
anism (11). In vitro, opiates cause contraction of rat aortic 
strips by a calcium-dependent mechanism (31,32) but 
induce vasodilation in rat mesenteric artery (31). Though 
enkephalins have various acHons in isolated cardiovas-
cular organs, the role of the peripheral opioid system in 
regulation of blood press ure and cardiac function in vivo 
is controversial. In the pithed rabbit, enkephalins have 
been reported to inhibit norepinephrine release in re-
sponse to sympathetic stimulation (33). However, exten-
sive studies conducted on the pithed rat (where the 
central nervous system and a11 reflexes are destroyed) 
failed to demonstrate eardiovascular responses to intra-
venous injections of various enkephalins selective for fl, 
a, or K opiate receptors (34,35). Furthermore, these studies 
also failed to show any role for enkephalins in modula-
tion of the sympatho-adrenomedullary system stimu-
lated through an· electrode placed in the spinal cord. 
Thus, although opiate receptors seem to be present in 
peripheral organs, the role of these receptors in modu~ 
lation of he art, kidney, and blood vessel function is still 
unclear. 
Enkephallns in Shock 
The endogenous opioid system has been implicated in 
the pathophysiology of shock. This suggestion was ini~ 
tia11y based on studies demonstrating that the opioid 
antagonist naloxone improves cardiovascular function 
and survival in some experimental shock models (36). 
Increased levels of enkephalins and beta-endorphin have 
been found in plasma and cerebrospinal fluid of animals 
exposed to hemorrhagic shock (13,37). Hemorrhagic 
shock was also shown to be associated with changes in 
opioid peptides and opioid receptors in specific brain 
nucIei of rats (38,39) which include selective up regula-
tion of 0 and K opiate receptors in the brain stern (38). 
FUTURE DIRECTIONS 
A major question left unanswered to date is: do enkeph-
alins play a crucial role in any particular physiological 
process1 This question sterns from observations showing 
that effective blockade of opioid receptors in vivo in 
normal humans or animals produces no appreciable car-
diovascular responses. However, the lack of cardiovas-
cular responses to naloxone (a potent opiate antagonist) 
might be the result of instantaneous adjustments in the 
hemodynamic balance due to the multiple systems in~ 
volved in cardiovascular regulation and therefore may 
not necessarily represent lack of enkephalin involve-
ment. Nevertheless, it seems at this time that the en~ 
kephalin system is activated as part of the general re-
sponse to stress. However, the exact role of the enkeph-
alins in the stress resp~mse is still unknown. Some reports 
indicate a depressor and detrimental outcome to the 
. enkephalin activation. but these views have been widely 
challenged. It is equally unknown which receptors are 
actually activated by endogenous enkephalins which 
show paar selectivity for the various opioid subtypes. 
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More selective and potent enkephalin agonists and es- . 
pecially antagonists must be developed in order to ex- , 
amine the specific role of each opioid receptor sub type 
in cardiovascular functions of normal and pathophysio-
logical states. 
KEY PLAYERS 
. 
N. J. GurU, Department of Surgery, University of lowa 
College ofMedicine, lewa City, lowa, USA. 
J. W. Holaday, Medical Neurosciences, Division Neuro-
psychiatry, Walter Reed Army Institute of Research/ 
Walter Reed Army Medical Center, Washington, D.C., 
USA. 
D. G. Reynolds, Department of Surgery, University of 
lewa, Hospital and Clinic, lewa City, lowa, USA. 
G. R. Van Loon, Department of Medicine and Pharma-
cology, University ofKentucky, Veterans Administration 
Medical Center, Lexington, Kentucky, USA. 
T. Vargish, Department of Surgery, West Virginia Uni-
versity Medical Center, Morgantown, West Virginia, 
USA. 
ACKNOWLEDGMENTS This work was supported by USUHS 
protocol No. R09211. The opinions or assertions contained 
herein are the private ones of the author{s) and are not to be 
construed as official or as necessarily reflecting the views of the 
Department of Defense or the Uniformed Services University of 
the Health Sciences. There is no objection to its presentaHon 
and/or publicaHon. The experiments reported herein were con-
ducted according to the principles set forth in the Guide for 
Care and Use of Laboratory Animals, Institute of Laboratory 
Animal Medicine, National Research Council, DHEW Publica-
Hon No. (NIH) 80-23, 1980. We wish to thank Laura L. Garza for 
the preparation of tbis manuscript. 
REFERENCE~ 
1. Khachaturian H, Lewis ME, Schafer MKH, Watson SI. Anat-
omy of the CNS opioid systems. Trends Neuro Sci 1985: 8:111-
9. 
2. Robson LE, Paterson 51, KosterIitz HW. Opiate receptors. In: 
Iversen LL, Iversen SD, Snyder SH, eds. Handbook of psycho-
pharmacology, vo117. New York: Plenum Press: 1983:13-80. 
3. Clement-Jones V, Lowry PJ, Ress LH, Besser GM. Met-
enkephalin circulates in human plasma. Nature 1980: 283:295-
7. 
4. Hahnbauer I, Kelly GD, Saiani L, Yang YT. [Met5]-Enkeph-
alin-like peptides of the adrenal medulla: Release by nerve 
stimulation and functional implications. Peptides 1982' 3:469-
73. ' 
5. Weihe E, McKnight AT, Corbett AD, KosterIitz HW. Proen-
kephalin- and prodynorphin-derived opioid peptides in guinea-
pig heart. Neuropeptides 1985: 5:453-6. 
anomalous properties in kidney and liver membranes. Mol 
Pharmacol1978; 14:69-76. 
10. Starke K, Schoffel E, Illes P. The sympathetic axons inner-
vating the sinus node of the rabbit possess presynaptic opioid K-
but not p.- or a-receptors. Naunyn-Schmiedeberg's Arch Phar-
maco11985: 329:206-9. 
11. Illes P, Bettermann R. Classification of presynaptic opioid 
receptors in the rabbit ear artery by competitive antagonists. 
Eur 1 Pharmacol1986; 122:153-6. 
12. Feuerstein G. The opioid system and central cardiovascular 
control: Analysis of controversies. Peptides 1985; 6:51-6. 
13. Lang RE, Buickner UB, Kempel B, et a1. Opioid peptides and 
blood pressure regulation. Clin Exp Hypertens 1982: A4(1-
2):249-69. 
14. Thornhill JA, Ewen M, Wilfong AA. Gregor L, Saunders WS. 
Pressor effects of systemic administration of methionine and 
leucine enkephalin in the conscious rat. Can J Physiol Phar-
maco11987; 64:1353-60. 
15. Feuerstein G, Faden AI. Differential cardiovascular effect 
ofmu, delta. and kappa opiate agonists at discrete hypothalamic 
sites in the anesthetized rat. Life Sei 1982: 31:2197-280. 
16. Punnen S, Willette R, Krieger AI, Sapru RN. Cardiovascular 
response to injections of enkephalin in the pressor area of the 
ventrolateral medulla. Neuropharmacology 1984: 23:939-46. 
17. Willette RN, Punnen 5, Krieger AI, Sapru HN. Hypertensive 
response following stimulation of opiate receptors in the caudal 
ventrolateral medulla. Neuropharmacology 1984; 23:401-6. 
18. Pfeiffer A, Feuerstein G, Kopin I], Faden AI. Cardiovascular 
and respiratory effect of mu, delta and kappa-opiate agonists 
micro-injected into the anterior hypothalamic brain area of 
awake rats. J Pharmacol Exp Ther 1983; 225:735-41. 
19. Pfeiffer A, Feuerstein G, Zerbe RL, Faden AI, Kopin IJ. p.-
Receptors mediate opioid cardiovascular effects at anterior hy-
pothalamic pathways. Endocrinology 1983: 113:929-38. 
,. , 
20. Feuerstein G. Dermorphin: Autonomic pharmacology and 
structure activity relationships in opiate peptides medicinal 
chemistry. NIDA Research Monographs 1985: 69:112-27. 
21. Diz DI, Vitale lA, ]acobowitz DM. Increases in heart rate 
and blood pressure produced by injections of dermorphin into 
discrete hypothalamic sites. Brain Res 1984; 294:47-57. 
22. Rassen AR, Feuerstein G, Faden AI. Selective cardiorespi-
ratory effects media ted by mu-opioid receptors in the nucleus 
ambiguus. Neuropharmacology 1984; 23:407-15. 
23. Hassen AR, Feuerstein G. p.-Opioid receptors inNTS elicit 
pressor responses via sympathetic pathways. Am J Physiol1987: 
252:H156-62. 
24. Gordon FJ. Central opioid receptors and baro-reflex control 
of sympathetic and cardiovascular function. J Pharm Exp Ther 
1986; 237:428-36. 
25. Feuerstein G, Faden AI. Cardiovascular effects of dynorphin 
A-{1-8), dynorphin A-(1-13) and dynorphin A-(1-17) microin-
jected into the preoptic medialis nucleus of the rat. Neuropep-
tides 1984: 5:295-8. 
6. Hughes 1, KosterIitz HW, Smith TW. The distribution of 
methionine-enkephalin and leucine-enkephalin in the brain 26. Hassen AH, Feuerstein G, Faden AI. Kappa opioid receptors 
and peripheral tissues. Br J Pharmacol1977: 61:639-47. modulate cardiorespiratory funcHon in hindbrain nuclei of rat. 
J Neurosci 1984: 4:2213-21. 
7. Lundberg]M, Hokfelt T, Anggard A, et aI. Peripheral peptide 
neurons: Distribution, axonal transport and some aspects on 
possible function. In: Costa E, Trabucchi M, eds. Neural peptides 
and neuronal communications. New York: Raven Press; 
1980:25-36. 
8. Krumins SA, Faden AL, Feuerstein G. Diprenophrine bind-
ing in rat heart: modulation of binding sites in the brain. 
Biochem Biophys Res Commun 1985; 127:120-8. 
9. Simantov, R, Childers SR, Snyder SH. 3H-opiate binding: 
282 JSI ATLAS OF SCIENCE: PHARMACOLOGY /1987 
27. Kiritsy-Roy JA, Appel NM, Bobbitt FG, Van Loon GR. Effects 
of mu-opioid receptor stimulation in the hypothalamic paraven-
tricular nucleus on basal and stress-induced catecholamine 
accretion and cardiovascular responses. J Pharm Exp Ther 1986: 
239:814-22. 
28. Appel NM, Kiritsy-Roy JA, Van Loon GR. Mu-receptors at 
discrete hypothalamic and brainstem sites mediate opioid pep-
tide-induced increases in central sympathetic outflow. Brain 
Res 1986; 378:8-20. 
29. Eiden LE, Ruth JA. Enkephalins modulate the responsive-
ness ofrat atria in vitro to norepinephrine. Peptides 1984; 3:475-
8. 
30. Fuder H, Buder M, Riers HO, Rothacher G. On the opioid 
receptor subtype inhibiting the evoked release of 3H-noradren-
aHne from guinea-pig atria in vitro. Naunyn-Schmiedeberg's 
Arch Pharmacol1986; 332:148-55. 
31. Altura BT, Gebrewald A, Altura BM. Comparative acUons 
of narcoties of large and mieroseopic blood vessels. Fed Proc 
1978; 37:471. 
32. Lee CH, Berkowitz BA. Stereoseleetive and calcium de-
pendent eontraetile effects of nareotie antagonist analgesics in 
the vaseular smooth museie of the rat. J Pharm Exp Ther 1977; 
198:347-56. 
33. Szabo B, Hedler L, Ensinger H, Starke K. Opioid peptides 
deerease noradrenaline release and blood pressure in the rabbit 
at peripheral reeeptors. Naunyn-Sehmiedeberg's Areh Phar-
maco11986; 332:50-6. 
34. Eimer! J, Feuerstein G. The effeet of p-, 6, " and E opioid 
reeeptors antagonists on heart rate and blood pressure of the 
pithed rat. Neuropeptides 1986: 8:351-8. 
35. Feuerstein G, Zukowska-Grojee Z. Effeet of dermorphin and 
morphine on the.sympathetie and cardiovascula'r system of the 
pithed rat. Neuropeptides 1987; 9:139-50. 
36. Holaday JW. Cardiovaseular effeets of endogenous opiate 
system. Annu Rev Pharmaeol Toxieol1983; 23:541-94. 
37. Elam R, Bergmann F, Feuerstein. G .. Sim~ltaneous eha~~es 
of catecholamines and leu-enkephahn-like Immuno-reaetivlty 
in plasma and eerebrospinal fluid of cats undergoing acute 
hemorrhage. Brain Res 1984; 303:313-7. 
38. Feuerstein G, Faden AI, Krumins SA. Alteration in opiate 
receptor binding after hemorrhagic shock. Eur J Pharmacol 
1984; 100:Z45-6. 
39. Feuerstein G, Molineaux'CJ, RoseIiberger JG, Zerbe RL, C~x 
BM, Faden AI. Hemorrhagic shoek and the eentral vasopreSSlD 
and opioid peptide system of rats. Am J Physiol1985; 249:E244-
50. 
RESEARCH FRONT 85-2696 
For further reading on this Research Front, you may 1) consult 
the Research Front Specialty Index in the Index to Scientific 
Reviews®, published by ISP', and Z) search ISI's online Sci-
Search® file on Datastar. 
ISI ATLAS OF SCIENCE: PHARMACOLOGY /1987 283 
